Stay updated on Daratumumab & DLI for Relapsed AML Clinical Trial

Sign up to get notified when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab & DLI for Relapsed AML Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The website footer revision changes from v3.8.0 to v3.8.1.
    Difference
    0.1%
    Check dated 2026-11-18T00:52:49.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The clinical trial record for daratumumab and donor lymphocyte infusion in relapsed acute myeloid leukemia is displayed with its study details, participation criteria, outcomes, record dates, and supporting documents. The record indicates the study was terminated due to poor accrual and is no longer recruiting participants.
    Difference
    58%
    Check dated 2026-11-10T19:06:59.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0. The study page continues to show a 403 Forbidden response.
    Difference
    0.2%
    Check dated 2026-11-03T19:16:01.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    A notice about NIH website terminology changes appears above the 403 error page, and the site revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T19:17:06.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page’s footer revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T20:13:54.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record content, indicating an access issue that hides the study details. This blocks viewing the core information for the NCT03537599 entry on ClinicalTrials.gov.
    Difference
    20%
    Check dated 2026-09-22T21:51:52.000Z thumbnail image

Stay in the know with updates to Daratumumab & DLI for Relapsed AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.